Friday, October 22, 2010

Pradaxa capsules dabigatran etexilate to prevent stroke in people with atrial fibrillation

US FDA approves Pradaxa capsules (dabigatran etexilate) to prevent stroke in people with atrial fibrillation
The US FDA has approved drug Pradaxa capsules (dabigatran etexilate) for the prevention of stroke and blood clots in patients suffering from atrial fibrillation a condition with abnormal heart rhythm.

Peoples suffering from Atrial fibrillation are more susceptible to formation of blood clot and brain stroke and formation of a block in heart , congestive heart failure , these conditions are life threatening .Atrial fibrillation is a condition where in the contraction of cardiac muscles do not occur in peculiar rhythm , instead they form a irregular contractions particularly in both atria so is the name “atrial fibrillation”.Atrial fibrillation as such is not life threatening but the aliments and conditions such as congestive heart failure, and brain stroke that it leads to are serious and life threatening,
In atrial fibrillation patients electrocardiogram ECG shows absence of P waves as the origin of impulse for contraction of heart muscles (Atria) is not from sinoatrial node rather the impulse for contraction is derived from other pulmonary veins.

Pradaxa capsules (dabigatran etexilate) is a anticoagulant drug which is a direct thrombin inhibitors (DTIs) which delay blood clotting by directly inhibiting the enzyme thrombin coagulation factor II (F2) which converts soluble fibrinogen into insoluble fibrin that forms a blood clot.

Clinical trial:
It was found in safety and efficacy study clinical trials of Pradaxa (dabigatran etexilate) compared to warfarin , that patients taking Pradaxa capsules (dabigatran etexilate) had fewer strokes than patients taking warfarin.

Adverse reactions:
Sever bleeding, uncomfortable feeling in the stomach (dyspepsia), stomach pain, nausea, heartburn, and bloating.

US FDA has approved Pradaxa with a medication guide that provides prompt information about risk of serious bleeding to patients. The guide is required to be distributed each time a patient buys this drug.
Pradaxa (dabigatran etexilate) is manufactured by pharmaceutical company, Boehringer Ingelheim Pharmaceuticals Inc. of Ridgefield, Conn., it is made available in 75 mg and 150 mg capsules.

No comments: